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Abstract 
Introduction: Cerebral venous thrombosis is a rare initial presentation of polycythemia. If 
diagnosed early, treatment can reduce mortality and morbidity significantly. Often it may 
present with headache as the only complaint, and thus the diagnosis is likely to be 
missed.  
Case Presentation: A medically stable 31-year-old male, a chronic smoker with a ~17 
pack-year history of smoking, was admitted to the emergency room with a 2-week 
history of gradually worsening, severe, throbbing headache in the occipital region 
sensitive to light. Initial neurological examination was positive only for some involuntary 
motor tics of the left leg. Initial laboratory workup showed hemoglobin of 20 g/dl and 
hematocrit of 56.5%. The carboxyhemoglobin level was normal, but the oxygen 
dissociation curve was shifted to the left. Further evaluation by MRI and MRA of the brain 
suggested extensive and complete thrombosis of the superior sagittal sinus, right 
transverse sinus and right sigmoid sinus with a small venous infarct in the right 
parafrontal region. Given that the patient first presented with a thrombotic event, 
workup for primary polycythemia and hypercoagulable disorders was carried out, 
including JAK2 mutation evaluation, which was negative. This left us with smoking as the 
only risk factor and possible cause for secondary polycythemia. He improved significantly 
with phlebotomy and anticoagulation treatment.  
Conclusion: This case illustrates a rare but severe complication of secondary 
polycythemia stressing the importance of being aware of the risk of developing cerebral 
thrombosis in patients with chronic smoking exposure. 
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Introduction 
Polycythemia is a rare condition involving myeloproliferative clonal cells. It is usually 
diagnosed based on the guidelines published by the Polycythemia Vera Study Group 
(PVSG), which are subject to constant revision by scientific researchers [1–4]. 
Polycythemia can present in a variety of ways in patients. Thrombosis is a serious 
complication of polycythemia and can lead to death in up to 8.3% of patients [5]. The 
etiology of thrombotic complications in polycythemia has not been outlined yet, but it is 
thought that leukocytosis and decreased blood flow due to elevated viscosity is the 
primary cause of thrombotic events [6–8]. 
Cerebral sinus thrombosis is considered a life-threatening condition. The incidence of 
cerebral venous thrombosis (CVT) is around 3–4 per million adults [9]. CVT can be 
caused by a variety of acquired or congenital diseases [10]. A polycythemia-related 
prothrombotic state can also present with CVT [10]. Smoking causes combined 
polycythemia secondary to reduced plasma volume and increased red cell mass due to 
hypoxia [11, 12]. Smoking-associated polycythemia can have serious initial presentation 
in the form of CVT, but there are limited data regarding the actual proportion of patients 
affected. A review of the literature did not reveal many anecdotal cases or series of case 
reports of fatal initial presentation in smokers. In the following, a patient with CVT and 
cerebral venous infarction as initial presentation of polycythemia related to smoking is 
discussed.  
Case Report 
The patient, a 31-year-old male, presented with a 2-week history of gradually worsening headache 
developing primarily in the occipital region, which was associated with photosensitivity. He described 
the pain as 10/10, being worse with any kind of movement and exposure to light. One week before, he 
had been admitted to the emergency room (ER) with similar complaints, and lumbar puncture and a CT 
scan of the brain were done. All results turned out to be normal and the patient received symptomatic 
management, but his condition further deteriorated, and he was again admitted to the ER with 
worsening symptoms.  
Except for the ER presentation, his past history and family history were negative for any kind of 
hematological disease. He was also not taking any medications. He smoked around 1 pack/day for the 
last 17 years. General examination showed him to be in acute painful distress. His headache exacerbated 
with walking or head movement. There was no detectable muscle weakness, but there were some 
involuntary motor tics of the left leg. He reported jerky involuntary on-off movements of the left thigh 
for a few days. The tip of his spleen was palpable. Ophthalmoscopically, papilledema was not found, and 
optic disc margins were sharp. The remainder of the systemic examination was unremarkable. His mini-
mental status examination was normal. 
Initial laboratory work in the ER showed a hemoglobin level of 20 g/dl and a hematocrit of 56.5%. 
He had leukocytosis (12.4 × 10
9/l). Platelet count was 3 × 10
5/dl. Cerebrospinal fluid examination 
revealed levels within the normal range. CSF opening pressure was not reported. In arterial blood gas 
analysis, carboxyhemoglobin was 2.3% (normal range 0.0–3.0%) and oxygen saturation level (p50) was 
23.08 mm Hg (normal 25.00–29.00 mm Hg), suggesting a shift of the oxygen dissociation curve to the 
left. Subsequently, he underwent imaging of the brain (MRI and MRA) that showed extensive 
thrombosis of the superior sagittal sinus extending to the right transverse and right sigmoid sinus region 
(fig. 1, fig. 2). There was also a small area of hypointense signaling on T1 and T2 suggestive of venous 
infarct with hemorrhage in the right parafrontal brain region.  
Neurology and hematology-oncology subspecialties were consulted, and the patient underwent 
workup for hypercoagulable disorders and polycythemia. The workup included lupus, antiphospholipid 
and cardiolipin antibody levels, JAK2 mutation, factor VIII level, antithrombin gene mutation and  
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factor V Leiden level, which were all negative. The erythropoietin level was 11 mIU/ml, which was 
within the normal range. The homocysteine level was mildly elevated but not to a level that suggested 
etiology. Comprehensive workup led to the diagnosis of smoking-induced polycythemia causing CVT. 
He was managed with therapeutic phlebotomy and body weight control, and heparin was followed 
by oral anticoagulation with warfarin. The last follow-up showed good recovery, with MRI and MRA 
suggesting clinical improvement (fig. 3, fig. 4), with headaches being under control. He stopped 
smoking, and his last hemoglobin level and hematocrit were 16.9 g/dl and 49.7%, respectively. 
Informed consent was obtained from the patient prior to the publication of this case report (available 
on request). 
Discussion 
CVT can be caused by a wide range of etiologies, including hypercoagulable disorders, 
such as factor V Leiden mutation, presence of anticardiolipin antibody, antithrombin 
gene mutation and polycythemia [11]. Polycythemia is a myeloproliferative disorder that 
is caused by a variety of etiologies [3] and can be absolute or relative. Absolute 
polycythemia can be primary (caused mainly by mutation in the JAK2 gene) or secondary 
[13]. Secondary polycythemia can be caused by elevated serum erythropoietin levels in 
response to chronic hypoxia leading to excess production of erythrocytes from the bone 
marrow. Smoking cigarettes creates a unique condition of combined polycythemia 
secondary to chronic hypoxia, leading to elevated red cell production due to an elevated 
carboxyhemoglobin level, with concomitant plasma volume reduction [11, 12]. To date, 
published studies suggest that polycythemia can present in a variety of ways, but specific 
initial presentation of smoker’s polycythemia, CVT, has not been reported so far [1–3]. 
CVT is a rare but serious complication of polycythemia [10]. It was suggested that 15% 
of patients entering the PVSG trial group had a documented major thrombotic event in 
the past. The mechanism by which polycythemia causes thrombosis is still under 
investigation, but, based on previous research, leukocytosis in association with stasis of 
blood causes hyperviscosity possibly leading to the development of thrombosis [6–8]. 
Smoking-induced polycythemia is a known condition, but its spectrum of presentation is 
still underreported due to the rarity of its occurrence. Smoker’s polycythemia presenting 
as CVT is not common, and there is a paucity of anecdotal evidence suggesting such an 
association. In our study, we aimed to determine the association between smoking-
induced polycythemia and CVT after ruling out the most common anticoagulation 
disorders and primary polycythemia etiologies. 
The diagnosis of polycythemia is usually based on the guidelines published by PVSG, 
which are constantly adapted based on novel research data [1, 2, 4, 14]. A group of 
researchers introduced the use of surrogate markers for the diagnosis of polycythemia, 
e.g. hemoglobin and hematocrit values instead of the red cell mass value, which is difficult 
to interpret and not commonly ordered by the clinicians for diagnosis [4]. Smoker’s 
polycythemia is usually diagnosed after exclusion of other causes of primary 
polycythemia, such as JAK2 mutation and erythropoietin level, and sometimes 
carboxyhemoglobin, arterial oxygen saturation concomitant with hemoglobin and 
hematocrit determination [1, 2, 12]. In our case, smoker’s polycythemia was diagnosed 
based on laboratory findings, including a left-shifted oxygen dissociation curve after 
ruling out primary polycythemia causes. The carboxyhemoglobin level was not elevated, 
but it is of note that the patient stopped smoking cigarettes after initiation of symptoms,  
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i.e. 1 week before hospital admission. Presence of the left shift of the oxygen dissociation 
curve suggested hypoxia mostly secondary to smoking.  
This case report is unique in a way: a young adult with gradually worsening headache 
and cerebral thrombosis as an initial manifestation of smoker’s polycythemia. The 
importance of addressing this topic is to add to the pool of evidence about smoker’s 
polycythemia. The report emphasizes the importance of being vigilant about the possible 
occurrence of CVT in smokers with no past history of polycythemia, the primary reason 
being the high rate of mortality associated with CVT. Various researchers have tried to 
assess the mortality of patients with untreated CVT, and in the ISCVT study 
(International Study on Cerebral Vein and Dural Sinus Thrombosis), this mortality 
amounted to 8.3% [5]. Evidence also indicates that untreated polycythemia can lead to 
death within 6–18 months [15]. Specific cause-related mortality of smoker’s polycythemia 
is not reported in the literature so far.  
Treatment of smoker’s polycythemia is usually directed towards acute treatment of 
disease and cessation of smoking as long-term benefit. In previous studies, smoking 
cessation resulted in significantly decreased hematocrit and hemoglobin levels [11, 12]. 
The patient presented here showed significant improvement following cessation of 
smoking and anticoagulation treatment, as evidenced by radiological imaging.  
There are some limitations to our study. During the evaluation of the patient, protein 
C and S, and antithrombin III levels were not checked. Also, workup for systemic 
inflammatory diseases causing an acquired hypercoagulable state, e.g. Behçet’s disease, 
was not carried out. Although our patient screened negative for occult malignancy, he is 
still under close follow-up for any signs of malignancy. The possibility of polycythemia 
vera still exists, as  20% of cases of polycythemia vera possess a negative JAK2 mutation. 
In addition, the patient is undergoing further workup for anticoagulation disorders once 
he is off anticoagulation. At present, despite the limitations of the study, smoking was the 
most likely etiology for the present findings; therefore, the authors would like to draw the 
attention to this unprecedented case in light of higher rates of adverse outcomes in 
undiagnosed cases. 
Conclusion 
Cigarette smoking has been associated with many medical problems, and one of those 
is polycythemia. This case demonstrates an unusual initial presentation of smoker’s 
polycythemia. The present case stresses that cerebral thrombosis should be borne in mind 
as initial presentation in smokers having headache. Early treatment can significantly 
reduce morbidity and mortality in patients with close follow-up. These patients should be 
followed up carefully by hematological and radiological investigation to establish the 
diagnosis and induce prompt treatment.  
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Fig. 1. MRI of the brain: vertical view at the time of presentation suggesting extensive thrombosis of 
the superior sagittal sinus. 
 
 
 
Fig. 2. MRI of the brain: horizontal view at the time of presentation showing thrombosis of the 
superior sagittal sinus extending into the transverse and sigmoid sinus regions. 
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Fig. 3. MRI of the brain: vertical view 3 months after treatment showing improvement with partial 
resolution of sagittal sinus thrombosis. 
 
 
 
Fig. 4. MRI of the brain: horizontal view 3 months after treatment showing improvement of transverse 
and sigmoid sinus thrombosis. 
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